by Blood Advances
Toxicities related to axicabtagene ciloleucel (axi-cel) can be safely and effectively managed, suggest findings from a single-center study.
by Clinical Cancer Research
While evidence suggests that increasing the share of stem cell-like memory T cells (TSCM) in chimeric antigen receptor (CAR) T-cell products might support immunotherapy for solid tumors, a Phase I...
by Blood Advances
Donor T cells that overexpress the protein BCL2, including those enriched after steroid exposure, protect against graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell...
by Clinical Cancer Research
Researchers have demonstrated the potential for selective irreversible electroporation (sIRE) to improve chimeric antigen receptor (CAR) T-cell function in solid tumors, thus lowering cancer...
by Margy MacMillan
Stepping into the role of ASTCT president over the past two months represents a meaningful culmination of my time serving and growing within our Society. From my first volunteer role in 2011 as...
by Margy MacMillan
This member spotlight features Margaret “Margy” MacMillan, MD, ASTCT president. In this Q&A, she shares insight into her career journey, how ASTCT has supported her growth,...